Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Dung Thi Le
Dung Thi Le
Video Player is loading.
In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
CRC Yields Most Prevalent Data at Recent GI Meeting
No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Multidisciplinary Care is ‘Incredibly Important’ for Managing GI Cancers
The Intricacies of Sequencing Immunotherapy in GI Cancers
Related Content
